Market Cap 281.01M
Revenue (ttm) 0.00
Net Income (ttm) -63.73M
EPS (ttm) N/A
PE Ratio 5.89
Forward PE 4.18
Profit Margin 0.00%
Debt to Equity Ratio 0.12
Volume 785,813
Avg Vol 928,012
Day's Range N/A - N/A
Shares Out 51.28M
Stochastic %K 51%
Beta 1.42
Analysts Strong Sell
Price Target $20.50

Company Profile

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based g...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 813 4701
Address:
6555 Carnegie Avenue, 4th Floor, Cleveland, United States
RDeneronow
RDeneronow Oct. 27 at 8:57 PM
$ABEO Ticking time bomb ⏲️ 💣 🚀 🚀 🚀 🚀 🚀 🚀 🚀 🚀
0 · Reply
Filvul
Filvul Oct. 27 at 6:52 PM
$ABEO booorrringg
0 · Reply
jamestrade07
jamestrade07 Oct. 27 at 2:02 PM
$ABEO seems like there is a coordinated short activity to keep the share price depressed. Maybe its done by some BP's trying to negotiate a cheap deal to buy Abeo. Abeo platform can generate many more new drugs and this should be very appealing to big pharms. The combination of cash& profitability in 26, approved product, advanced drug discovery platform and depressed share price is what BP's are eyeing these days..
0 · Reply
FitzCatalyst
FitzCatalyst Oct. 27 at 12:55 PM
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Oct. 25 at 2:17 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ABEO Current Share Price: $5.45 Contracts: $ABEO June 18, 2026 $10 Calls Scale in: $1.28- $1.57 Scale out: $1.99-$2.56 Can Easily Capture: 60% ROI Blended DTE: 238 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
commoncentsinvestor
commoncentsinvestor Oct. 24 at 6:01 PM
$ABEO The battle between shorts and longs spent a few weeks at and around $5.40. Seems the longs have won and the new battle is at $5.50. This will be much more fun when the battles are at $10, $20, and $40.
0 · Reply
TragicRain
TragicRain Oct. 24 at 3:04 PM
$ABEO - Glad I got it so far....
0 · Reply
commoncentsinvestor
commoncentsinvestor Oct. 24 at 2:47 PM
$ABEO Newcomers to ABEO should be aware that the company has net cash of $4.00 per share. So at the current price of around $5.50, investors entering now are basically paying $1.50 per share for the entire company less cash. If the company only does a small share of what is predicted, this could be one of the most profitable investments ever.
1 · Reply
acm20
acm20 Oct. 24 at 4:03 AM
M&A Potential in 2025 Based on recent developments (as of October 23, 2025), both $MNKD (MannKind Corporation) and $ABEO (Abeona Therapeutics) exhibit strong M&A potential in the biotech sector. The industry is seeing accelerated deal activity—Q3 2025 M&A volume hit $30.8B, up 25% YoY—driven by Big Pharma's push into rare diseases, inhaled therapies, and gene editing amid deregulation. MNKD's recent acquisition positions it as a consolidator, while ABEO's undervalued gene therapy pipeline makes it an attractive bolt-on target. Analysts (e.g., Zacks, HC Wainwright) rate both as "Strong Buy," with M&A as a top catalyst for 50-100% upside. - Source: Grok
1 · Reply
RDeneronow
RDeneronow Oct. 23 at 10:59 PM
3 · Reply
Latest News on ABEO
Abeona Therapeutics Inc. (ABEO) Q2 2025 Earnings Call Transcript

Aug 19, 2025, 3:25 PM EDT - 2 months ago

Abeona Therapeutics Inc. (ABEO) Q2 2025 Earnings Call Transcript


Abeona Therapeutics Inc. (ABEO) Q1 2025 Earnings Call Transcript

May 16, 2025, 1:37 AM EDT - 5 months ago

Abeona Therapeutics Inc. (ABEO) Q1 2025 Earnings Call Transcript


US FDA approves Abeona's skin disorder therapy

Apr 29, 2025, 6:06 AM EDT - 6 months ago

US FDA approves Abeona's skin disorder therapy


Pz-Cel Has Massive Potential For RDEB Patients

Apr 21, 2025, 10:00 AM EDT - 6 months ago

Pz-Cel Has Massive Potential For RDEB Patients


Abeona Therapeutics Inc. (ABEO) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 3:20 PM EDT - 7 months ago

Abeona Therapeutics Inc. (ABEO) Q4 2024 Earnings Call Transcript


RDeneronow
RDeneronow Oct. 27 at 8:57 PM
$ABEO Ticking time bomb ⏲️ 💣 🚀 🚀 🚀 🚀 🚀 🚀 🚀 🚀
0 · Reply
Filvul
Filvul Oct. 27 at 6:52 PM
$ABEO booorrringg
0 · Reply
jamestrade07
jamestrade07 Oct. 27 at 2:02 PM
$ABEO seems like there is a coordinated short activity to keep the share price depressed. Maybe its done by some BP's trying to negotiate a cheap deal to buy Abeo. Abeo platform can generate many more new drugs and this should be very appealing to big pharms. The combination of cash& profitability in 26, approved product, advanced drug discovery platform and depressed share price is what BP's are eyeing these days..
0 · Reply
FitzCatalyst
FitzCatalyst Oct. 27 at 12:55 PM
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Oct. 25 at 2:17 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ABEO Current Share Price: $5.45 Contracts: $ABEO June 18, 2026 $10 Calls Scale in: $1.28- $1.57 Scale out: $1.99-$2.56 Can Easily Capture: 60% ROI Blended DTE: 238 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
commoncentsinvestor
commoncentsinvestor Oct. 24 at 6:01 PM
$ABEO The battle between shorts and longs spent a few weeks at and around $5.40. Seems the longs have won and the new battle is at $5.50. This will be much more fun when the battles are at $10, $20, and $40.
0 · Reply
TragicRain
TragicRain Oct. 24 at 3:04 PM
$ABEO - Glad I got it so far....
0 · Reply
commoncentsinvestor
commoncentsinvestor Oct. 24 at 2:47 PM
$ABEO Newcomers to ABEO should be aware that the company has net cash of $4.00 per share. So at the current price of around $5.50, investors entering now are basically paying $1.50 per share for the entire company less cash. If the company only does a small share of what is predicted, this could be one of the most profitable investments ever.
1 · Reply
acm20
acm20 Oct. 24 at 4:03 AM
M&A Potential in 2025 Based on recent developments (as of October 23, 2025), both $MNKD (MannKind Corporation) and $ABEO (Abeona Therapeutics) exhibit strong M&A potential in the biotech sector. The industry is seeing accelerated deal activity—Q3 2025 M&A volume hit $30.8B, up 25% YoY—driven by Big Pharma's push into rare diseases, inhaled therapies, and gene editing amid deregulation. MNKD's recent acquisition positions it as a consolidator, while ABEO's undervalued gene therapy pipeline makes it an attractive bolt-on target. Analysts (e.g., Zacks, HC Wainwright) rate both as "Strong Buy," with M&A as a top catalyst for 50-100% upside. - Source: Grok
1 · Reply
RDeneronow
RDeneronow Oct. 23 at 10:59 PM
3 · Reply
commoncentsinvestor
commoncentsinvestor Oct. 22 at 1:45 PM
$ABEO Abeona Therapeutics Inc. (NASDAQ:ABEO) is one of the stocks under $10 to buy now. https://www.msn.com/en-us/money/markets/abeona-therapeutics-ascellahealth-partner-for-commercialization-of-zevaskyn-gene-therapy/ar-AA1JGSIY?ocid=finance-verthp-feeds&apiversion=v2&noservercache=1&domshim=1&renderwebcomponents=1&wcseo=1&batchservertelemetry=1&noservertelemetry=1
0 · Reply
invest2021_now
invest2021_now Oct. 22 at 1:16 PM
0 · Reply
commoncentsinvestor
commoncentsinvestor Oct. 21 at 3:09 PM
$ABEO I invest on fundamentals rather than Technical Analysis. But maybe someone who is knowledgeable about TA could explain what the latest recurring pattern in the ABEO price might mean. For quite some time the price starts off the day about where it previously closed and then all of a sudden it drops down usually around 2 to 3 per cent. Than in a short while it roars back and then the rest of the day trades fairly normally and than closes around where it started or slightly higher. Any particular meaning to this?
1 · Reply
TragicRain
TragicRain Oct. 21 at 2:41 PM
$ABEO - Took a long position - Looking forward to growth. Nice little HSA play for me.
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Oct. 21 at 12:21 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ABEO Current Share Price: $5.38 Contracts: $ABEO March 20, 2026 $6 Calls Scale in: $0.90- $1.10 Scale out: $1.40-$1.80 Can Easily Capture: 60% ROI Blended DTE: 152 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
edelhead
edelhead Oct. 20 at 6:21 PM
$ABEO An 11th member of the leadership team added today. That is a bullish move by management!
0 · Reply
commoncentsinvestor
commoncentsinvestor Oct. 20 at 5:51 PM
$ABEO Obvious short attacks being stymied. That can be the beginning of a big run. Sure would be nice if they would announce that the first patient received the procedure.
0 · Reply
creditgoo
creditgoo Oct. 20 at 11:55 AM
$ABEO shorting more today
1 · Reply
Filvul
Filvul Oct. 20 at 11:41 AM
$ABEO one more QTC by the end of the month would be amazing;)
1 · Reply
Wazaby44
Wazaby44 Oct. 20 at 10:16 AM
$ABEO extremely bullish, catalyst ahead nov 17th - ranging on 5.73/5.22, ready to bounce back ! It's going to be...
1 · Reply
Goodstockday
Goodstockday Oct. 19 at 1:29 AM
$ABEO What does this stock need to make a nice gain? They need to report that all is going to plan. They do not need to do anything extraordinary. I am looking forward to the quarterly report!
0 · Reply
commoncentsinvestor
commoncentsinvestor Oct. 18 at 9:26 PM
$ABEO Biotech Firm Abeona Therapeutics Positioned for Significant Growth "While numerous biotechnology companies face challenging market conditions, Abeona Therapeutics is distinguishing itself with a series of promising developments. From achieving critical regulatory milestones to posting unexpected financial gains, this emerging biotech firm is capturing investor attention. The question now is whether its recent positive momentum can translate into a major market breakthrough." https://www.aktiencheck.de/news/Artikel-Biotech_Firm_Abeona_Therapeutics_Positioned_for_Significant_Growth-19117851
0 · Reply